Kim Ge, as the first domestic company, was approved by Viagra, quickly occupied the market once it was launched.
According to a report on July 19th of the China Securities Journal, recently, a real -name open letter against Li Chuyuan, chairman of Guangyao Group Li Chuyuan, has made the interests of China Viagra's interests surfaced.
On July 18th, the publisher of the open letter Beijing Kangyeyuan Investment Consultant Co., Ltd. (Kangye Yuan) said that Bai Yunshan and his chairman Li Chuyuan had information disclosure, concealing profits and income, fake financial data, tax evasion, etc.Behavior.
Baiyunshan's controlling shareholder Guangyao Group issued a statement on the afternoon of July 19 responded that the information involved in the report letter was seriously inconsistent with the facts. Bai Yunshan Technology has been operating in accordance with the company's articles of association according to law.It will be held accountable in accordance with legal procedures.
Bai Yunshan and the chairman were reported
On July 18, Beijing Kangye Yuan Investment Consultant Co., Ltd. published an open letter entitled to the illegal and disciplinary of Li Chuyuan, the chairman of the Guangyao Group, and accused Bai Yunshan and his chairman Li Chuyuan suspected of violating the relevant securities laws and corporate laws.Unreal, concealment of profits and income, fraudulent financial data, tax evasion, directly infringe on the interests of shareholders and small and medium shareholders of listed companies, and indirectly infringe on the rights and interests of partnerships.
(Report letter from Kangye)
Data from Tianyan Check shows that Kangye Yuan was established on June 22, 2009. The legal representative is Zhang Jianrong, with a registered capital of 1 million yuan and investing in three companies. Guangzhou Baiyunshan Pharmaceutical Technology Development Co., Ltd. (referred to as Baiyunshan Technology) is one of them.Kangye Yuan holds 49%of Baiyunshan Technology, and listed companies Baiyunshan holds 51%of Baiyunshan Technology.
There are three main aspects of the content of Bai Yunshan and its chairman:
First, since the product of Baiyunshan Technology, Baiyunshan Technology, Xiaobian Note), a subsidiary of Baiyunshan, Kang Yeyuan has not obtained a complete financial accounting report as a shareholder;
Second, although Jin Ge's profits are huge, Kang Yeyuan has not received any benefits as a shareholder;
Third, in the environment of the two -vote system, without the consent of Kangye Yuan, Li Chuyuan, chairman of Guangyao Group, transferred Bai Yunshan Technology's Bai Ding products to Shandong Ruiyang Pharmaceutical to harm Kangye Yuan's rights and interests.
In addition, Kangye Yuan also pointed out that there are problems such as fakes and concealment of financial data on the income of Jin Ge's products through a set of raw material data.
The dispute between the current interests of China Viagra
It is not difficult to find from the report letter from Kangyeyuan that the content of the report is mostly centered around Baiyunshan's fist product Jin Ge.Kim Ge is known as China Viagra. Its scientific name is citron acid Sidda, which is a oral medicine for the treatment of penile erectile dysfunction (ED).Pharmaceutical production approval.
Since it is the first domestic enterprise, it is approved by the domestic enterprise. Since its listing in 2014, China Veori Jinsuo has successfully seized some markets in a short time because the price is much lower than the market, and the profits are quite considerable.In the report letter, Kang Yeyuan pointed out that since its listing, Jin Ge's sales have reached more than 2 billion yuan and profit of more than 1 billion yuan.
The 2018 annual report of Baiyunshan also showed that Jin Ge's output in 2018 was 49.0308 million pieces, with sales of 47.739 million pieces, an increase of 20.45%year -on -year.At the same time, Jin Ge achieved operating income of 662 million yuan in 2018, an increase of 17.67%year -on -year, while operating costs were 83.7454 million yuan.
The controlling shareholder claims that the content of the report does not match the facts
Regarding the report letter from Kangye Yuan, Baiyunshan Holding shareholder Guangyao Group issued a statement on the afternoon of July 19 stated that the company was concerned about the company's subordinate third -level joint venture Guangzhou Baiyunshan Pharmaceutical Technology Co., Ltd., another shareholder of Beijing Kangyeyuan Investment Consultant Co., Ltd.Posted an open letter, the information involved in the letter is seriously inconsistent with the facts:
1. After understanding Bai Yunshan Technology, the company has been operating the company in accordance with the company's articles of association according to laws and regulations, and held a board and shareholders' meeting in accordance with the company's articles of association.
2. Regarding the related issues of Jin Ge, Bai Yunshan Technology and related parties have always actively actively communicated with Kangye Yuan, but did not reach an agreement.
3. In view of the serious inconsistency of the public letter content with the facts, it has created rumors to discredit the company and the general manager of the company and Bai Yunshan Science and Technology Xiao Rongming, which has caused serious adverse effects. The company has reported to the public security organs and was accepted.The company will investigate the relevant responsibility of Kaiye Yuan in accordance with legal procedures.
